Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Daniel Fernández-Villa, PhD
CONTACT
Lead
Unifarco SpA
Psoriasis is a chronic, immune-mediated inflammatory skin disease frequently associated with impaired skin barrier function, dryness, pruritus, and reduced quality of life. Narrowband UVB phototherapy is a standard-of-care treatment for mild-to-moderate plaque psoriasis, but it can further compromise skin barrier integrity and hydration. Emollients containing ceramides, cholesterol, fatty acids and urea have been reported to support barrier repair, reduce transepidermal water loss, and improve tolerance to phototherapy when used as adjuvant treatments. Ceramol PSOR cream is a CE-marked (Class IIa) medical device manufactured by Unifarco S.p.A., formulated with ceramides, cholesterol, fatty acids and urea, indicated for the hyperkeratotic and scaly forms of mild and/or moderate psoriasis. Participants will be randomized 1:1 to receive either Ceramol PSOR cream or a cosmetically similar comparator emollient cream lacking the specific functional ingredients, applied topically once daily as an adjuvant to their narrowband UVB phototherapy cycle. The study includes three in-person visits: a baseline visit (V1, day 0, including informed consent, eligibility confirmation, and randomization), a follow-up visit (V2, after 12 ± 3 UVB sessions) and an end-of-study visit (V3, after 36 ± 3 UVB sessions). A sample size of 128 participants (allowing \~10% loss to follow-up) will be recruited across 4 sites in Spain.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
